{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:31:11Z","timestamp":1790397071601,"version":"4.1.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Real-world data on effectiveness and safety of a single non-vitamin K antagonist oral anticoagulant in the Chinese population with atrial fibrillation (AF) are limited. This study reports characteristics of patients treated with edoxaban and factors associated with dosing patterns from routine care in China. ETNA-AF-China (NCT04747496) is a multicentre, prospective, observational study enrolling edoxaban-treated patients from four economic regions with a targeted 2-year follow-up. Of the 4930 patients with AF (mean age: 70.2\u2009\u00b1\u20099.5\u00a0years; male, 57.1%), the mean creatinine clearance (CrCl), CHA<jats:sub>2<\/jats:sub>DS<jats:sub>2<\/jats:sub>-VASc, and HAS-BLED scores were 71.2\u00a0mL\/min, 2.9, and 1.6. Overall, 6.4% of patients were perceived as frail by investigators. Available label dose reduction criteria (N\u2009=\u20094232) revealed that 3278 (77.5%) patients received recommended doses and 954 (22.5%) non-recommended doses. Northeast (53.0%) and West (43.1%) regions had the highest prescriptions of 60\u00a0mg and 30\u00a0mg recommended doses, respectively. Non-recommended 30\u00a0mg doses were more frequently prescribed in patients with antiplatelet use and history of heart failure than recommended 60\u00a0mg. Multivariate analysis identified advanced age as the strongest associated factor with non-recommended doses. Frailty had the strongest association with 30\u00a0mg except for age, and history of TIA was the most relevant factor associated with 60\u00a0mg. In conclusion,\u00a0patients in the ETNA-AF-China study were predominantly aged 65\u00a0years and older, had mild-to-moderate renal impairment and good label adherence. Advanced age was associated with non-recommended doses, with frailty most common for non-recommended 30\u00a0mg and a history of TIA for the non-recommended 60\u00a0mg dose.<\/jats:p>","DOI":"10.1038\/s41598-024-51776-3","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T11:02:05Z","timestamp":1706871725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registry"],"prefix":"10.1038","volume":"14","author":[{"given":"Xueyuan","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebin","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingzhi","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guotian","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manhua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Unverdorben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ETNA-AF-China Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuehui","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhisheng","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cangsang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huifang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suxin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongqi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyou","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiafu","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwen","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianjun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouqing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zebin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xubo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengli","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenggui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fucheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caixia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiebi","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanmin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meise","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosheng","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baopeng","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boli","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjiang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlin","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingzhen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fujie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"51776_CR1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ijcard.2018.05.131","volume":"271","author":"X Wang","year":"2018","unstructured":"Wang, X. et al. Prevalence of atrial fibrillation in different socioeconomic regions of China and its association with stroke: Results from a national stroke screening survey. Int. J. Cardiol. 271, 92\u201397 (2018).","journal-title":"Int. J. Cardiol."},{"key":"51776_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100439","volume":"23","author":"S Shi","year":"2022","unstructured":"Shi, S. et al. Prevalence and risk of atrial fibrillation in China: A national cross-sectional epidemiological study. Lancet Reg. Health West Pac. 23, 100439 (2022).","journal-title":"Lancet Reg. Health West Pac."},{"issue":"5","key":"51776_CR3","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/svn-2021-001374","volume":"7","author":"YJ Wang","year":"2022","unstructured":"Wang, Y. J. et al. China Stroke Statistics: An update on the 2019 report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations. Stroke Vasc. Neurol. 7(5), 415\u2013450 (2022).","journal-title":"Stroke Vasc. Neurol."},{"issue":"7","key":"51776_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/heartjnl-2020-317915","volume":"107","author":"X Du","year":"2021","unstructured":"Du, X. et al. Atrial fibrillation prevalence, awareness and management in a nationwide survey of adults in China. Heart 107(7), 535\u2013541 (2021).","journal-title":"Heart"},{"key":"51776_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/7372129","volume":"2019","author":"Y Sun","year":"2019","unstructured":"Sun, Y. et al. Stroke risk status, anticoagulation treatment, and quality-of-life in Chinese patients with atrial fibrillation: China Registry of Atrial Fibrillation (CRAF). Cardiovasc. Ther. 2019, 1\u201310 (2019).","journal-title":"Cardiovasc. Ther."},{"issue":"12","key":"51776_CR6","doi-asserted-by":"publisher","first-page":"e897","DOI":"10.1016\/S2468-2667(21)00228-0","volume":"6","author":"Q Ma","year":"2021","unstructured":"Ma, Q. et al. Temporal trend and attributable risk factors of stroke burden in China, 1990\u20132019: An analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 6(12), e897-906 (2021).","journal-title":"Lancet Public Health."},{"key":"51776_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.581293","volume":"12","author":"NN Shen","year":"2021","unstructured":"Shen, N. N. et al. Real-world prevalence of direct oral anticoagulant off-label doses in atrial fibrillation: An epidemiological meta-analysis. Front. Pharmacol. 12, 581293 (2021).","journal-title":"Front. Pharmacol."},{"issue":"1","key":"51776_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jamacardio.2015.0382","volume":"1","author":"JP Piccini","year":"2016","unstructured":"Piccini, J. P. & Fonarow, G. C. Preventing stroke in patients with atrial fibrillation\u2014A steep climb away from achieving peak performance. JAMA Cardiol. 1(1), 63 (2016).","journal-title":"JAMA Cardiol."},{"key":"51776_CR9","unstructured":"Package Insert of Edoxaban Tosilate Tablets [Internet]. National Medical Products Administration, Center for Drug Evaluation. https:\/\/www.cde.org.cn\/hymlj\/download\/sms\/9075643027a6bbcce0d1a35df6bf6fb3"},{"issue":"22","key":"51776_CR10","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano, R. P. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 369(22), 2093\u20132104 (2013).","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"51776_CR11","doi-asserted-by":"publisher","first-page":"573","DOI":"10.3390\/jcm10040573","volume":"10","author":"R De Caterina","year":"2021","unstructured":"De Caterina, R. et al. Safety and effectiveness of edoxaban in atrial fibrillation patients in routine clinical practice: One-year follow-up from the global noninterventional ETNA-AF program. J. Clin. Med. 10(4), 573 (2021).","journal-title":"J. Clin. Med."},{"issue":"FI1","key":"51776_CR12","doi-asserted-by":"publisher","first-page":"f30","DOI":"10.1093\/ehjcvp\/pvaa079","volume":"7","author":"JR de Groot","year":"2021","unstructured":"de Groot, J. R. et al. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. Eur. Heart J. Cardiovasc. Pharmacother. 7(FI1), f30\u2013f39 (2021).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"1","key":"51776_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1093\/ehjcvp\/pvac042","volume":"9","author":"P Kirchhof","year":"2023","unstructured":"Kirchhof, P. et al. Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care. Eur. Heart J. Cardiovasc. Pharmacother. 9(1), 47\u201357 (2023).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"3","key":"51776_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/joa3.12332","volume":"36","author":"T Yamashita","year":"2020","unstructured":"Yamashita, T., Koretsune, Y., Nagao, T. & Shiosakai, K. Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): One-year safety and effectiveness analyses. J. Arrhythmia. 36(3), 395\u2013405 (2020).","journal-title":"J. Arrhythmia."},{"issue":"2","key":"51776_CR15","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1002\/joa3.12520","volume":"37","author":"T Yamashita","year":"2021","unstructured":"Yamashita, T., Koretsune, Y., Nagao, T. & Shiosakai, K. Safety and effectiveness of edoxaban in Japanese patients with nonvalvular atrial fibrillation: Final report of a two-year postmarketing surveillance study (ETNA-AF-Japan). J. Arrhythmia. 37(2), 370\u2013383 (2021).","journal-title":"J. Arrhythmia."},{"issue":"22","key":"51776_CR16","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.3390\/jcm10225337","volume":"10","author":"EK Choi","year":"2021","unstructured":"Choi, E. K. et al. Clinical events with edoxaban in South Korean and Taiwanese atrial fibrillation patients in routine clinical practice. J. Clin. Med. 10(22), 5337 (2021).","journal-title":"J. Clin. Med."},{"issue":"11","key":"51776_CR17","first-page":"1844","volume":"24","author":"DA Gorog","year":"2022","unstructured":"Gorog, D. A. et al. Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. EP Eur. 24(11), 1844\u20131871 (2022).","journal-title":"EP Eur."},{"issue":"4","key":"51776_CR18","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jacasi.2022.05.005","volume":"2","author":"CE Chiang","year":"2022","unstructured":"Chiang, C. E. et al. Stroke prevention in atrial fibrillation. JACC Asia. 2(4), 395\u2013411 (2022).","journal-title":"JACC Asia."},{"issue":"5","key":"51776_CR19","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1097\/JCMA.0000000000000516","volume":"84","author":"TF Chao","year":"2021","unstructured":"Chao, T. F. et al. Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program. J. Chin. Med. Assoc. 84(5), 485 (2021).","journal-title":"J. Chin. Med. Assoc."},{"issue":"2","key":"51776_CR20","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1093\/ehjcvp\/pvy041","volume":"5","author":"P Amarenco","year":"2019","unstructured":"Amarenco, P. et al. Outcomes associated with non-recommended dosing of rivaroxaban: Results from the XANTUS study. Eur. Heart J. Cardiovasc. Pharmacother. 5(2), 70\u201379 (2019).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"12","key":"51776_CR21","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jacc.2020.07.045","volume":"76","author":"AJ Camm","year":"2020","unstructured":"Camm, A. J. et al. Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants. J. Am. Coll. Cardiol. 76(12), 1425\u20131436 (2020).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"12","key":"51776_CR22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/clc.23279","volume":"42","author":"R De Caterina","year":"2019","unstructured":"De Caterina, R. et al. The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: Rationale and design. Clin. Cardiol. 42(12), 1147\u20131154 (2019).","journal-title":"Clin. Cardiol."},{"issue":"2","key":"51776_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2459\/JCM.0000000000000737","volume":"20","author":"R De Caterina","year":"2019","unstructured":"De Caterina, R. et al. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. J. Cardiovasc. Med. 20(2), 97\u2013104 (2019).","journal-title":"J. Cardiovasc. Med."},{"issue":"6","key":"51776_CR24","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2215\/CJN.06870909","volume":"5","author":"WM Michels","year":"2010","unstructured":"Michels, W. M. et al. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin. J. Am. Soc. Nephrol. 5(6), 1003\u20131009 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"11","key":"51776_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","volume":"158","author":"PE Stevens","year":"2013","unstructured":"Stevens, P. E. & Levin, A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline. Ann. Intern. Med. 158(11), 825\u2013830 (2013).","journal-title":"Ann. Intern. Med."},{"issue":"9","key":"51776_CR26","first-page":"1404","volume":"24","author":"I Diemberger","year":"2022","unstructured":"Diemberger, I. et al. Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: An ETNA-AF-Europe sub-analysis. EP Eur. 24(9), 1404\u20131411 (2022).","journal-title":"EP Eur."},{"issue":"5","key":"51776_CR27","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3322\/caac.21406","volume":"67","author":"CG Ethun","year":"2017","unstructured":"Ethun, C. G. et al. Frailty and cancer: Implications for oncology surgery, medical oncology, and radiation oncology. CA Cancer J. Clin. 67(5), 362\u2013377 (2017).","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"51776_CR28","first-page":"860","volume":"80","author":"T Yamashita","year":"2016","unstructured":"Yamashita, T. et al. Edoxaban vs. warfarin in East Asian patients with atrial fibrillation\u2014An ENGAGE AF-TIMI 48 subanalysis. Circ. J. Off. J. Jpn. Circ. Soc. 80(4), 860\u2013869 (2016).","journal-title":"Circ. J. Off. J. Jpn. Circ. Soc."},{"issue":"4","key":"51776_CR29","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/joa3.12073","volume":"34","author":"Y Kim","year":"2018","unstructured":"Kim, Y. et al. XANAP: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia. J. Arrhythmia. 34(4), 418\u2013427 (2018).","journal-title":"J. Arrhythmia."},{"issue":"4","key":"51776_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/clc.22649","volume":"40","author":"W Li","year":"2017","unstructured":"Li, W. et al. Efficacy and safety of dabigatran, rivaroxaban, and warfarin for stroke prevention in Chinese patients with atrial fibrillation: The Hong Kong Atrial Fibrillation Project. Clin. Cardiol. 40(4), 222\u2013229 (2017).","journal-title":"Clin. Cardiol."},{"issue":"3","key":"51776_CR31","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/joa3.12321","volume":"36","author":"C Ma","year":"2020","unstructured":"Ma, C. et al. Stroke prevention in atrial fibrillation changes after dabigatran availability in China: The GLORIA-AF registry. J. Arrhythmia. 36(3), 408\u2013416 (2020).","journal-title":"J. Arrhythmia."},{"issue":"11","key":"51776_CR32","doi-asserted-by":"publisher","first-page":"3920","DOI":"10.1016\/j.sapharm.2022.06.002","volume":"18","author":"S Salmasi","year":"2022","unstructured":"Salmasi, S. et al. Oral anticoagulant adherence and switching in patients with atrial fibrillation: A prospective observational study. Res. Soc. Adm. Pharm. 18(11), 3920\u20133928 (2022).","journal-title":"Res. Soc. Adm. Pharm."},{"issue":"7","key":"51776_CR33","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1161\/STROKEAHA.116.012988","volume":"47","author":"SS Chang","year":"2016","unstructured":"Chang, S. S. et al. Current status and time trends of oral anticoagulation use among Chinese patients with nonvalvular atrial fibrillation: The Chinese atrial fibrillation registry study. Stroke. 47(7), 1803\u20131810 (2016).","journal-title":"Stroke."},{"issue":"10","key":"51776_CR34","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2217\/fca-2022-0050","volume":"18","author":"R Wang","year":"2022","unstructured":"Wang, R. et al. Real-world treatment patterns and stroke risks among patients with atrial fibrillation in China. Future Cardiol. 18(10), 787\u2013796 (2022).","journal-title":"Future Cardiol."},{"key":"51776_CR35","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.12659\/MSM.915875","volume":"25","author":"C Liu","year":"2019","unstructured":"Liu, C. et al. Long-term persistence with newly-initiated warfarin or non-VKA oral anticoagulant (NOAC) in patients with non-valvular atrial fibrillation: Insights from the prospective China-AF registry. Med. Sci. Monit. 25, 2649\u20132657 (2019).","journal-title":"Med. Sci. Monit."},{"issue":"1","key":"51776_CR36","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/joa3.12149","volume":"35","author":"T Yamashita","year":"2019","unstructured":"Yamashita, T., Koretsune, Y., Ishikawa, M., Shiosakai, K. & Kogure, S. Postmarketing surveillance on clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): Three-month interim analysis results. J. Arrhythmia. 35(1), 121\u2013129 (2019).","journal-title":"J. Arrhythmia."},{"issue":"1","key":"51776_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12872-019-1144-x","volume":"19","author":"R De Caterina","year":"2019","unstructured":"De Caterina, R. et al. Characteristics of patients initiated on edoxaban in Europe: Baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe). BMC Cardiovasc. Disord. 19(1), 165 (2019).","journal-title":"BMC Cardiovasc. Disord."},{"key":"51776_CR38","unstructured":"Statistical Communiqu\u00e9 of the People\u2019s Republic of China on the 2021 National Economic and Social Development [Internet]. National Bureau of Statistics of China; 2021 [cited 2023 Dec 12]. https:\/\/www.gov.cn\/xinwen\/2021-02\/03\/content_5584517.htm"},{"key":"51776_CR39","unstructured":"China Health Statistical Yearbook 2022 [Internet]. National Health Commission of China; 2022 [cited 2023 Dec 12]. http:\/\/www.nhc.gov.cn\/mohwsbwstjxxzx\/tjtjnj\/202305\/6ef68aac6bd14c1eb9375e01a0faa1fb\/files\/b05b3d958fc546d98261d165cea4adba.pdf"},{"issue":"FI1","key":"51776_CR40","doi-asserted-by":"publisher","first-page":"f81","DOI":"10.1093\/ehjcvp\/pvaa020","volume":"7","author":"M Vitolo","year":"2021","unstructured":"Vitolo, M., Lane, D. A., Boriani, G. & Lip, G. Y. H. The importance of adherence and persistence with oral anticoagulation treatment in patients with atrial fibrillation. Eur. Heart J. Cardiovasc. Pharmacother. 7(FI1), f81\u2013f83 (2021).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"3","key":"51776_CR41","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3349\/ymj.2019.60.3.277","volume":"60","author":"SR Lee","year":"2019","unstructured":"Lee, S. R. et al. Label adherence for non-vitamin K antagonist oral anticoagulants in a prospective cohort of Asian patients with atrial fibrillation. Yonsei Med. J. 60(3), 277 (2019).","journal-title":"Yonsei Med. J."},{"issue":"2","key":"51776_CR42","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1093\/ehjqcco\/qcab025","volume":"8","author":"T Yamashita","year":"2022","unstructured":"Yamashita, T. et al. Two-year outcomes of more than 30000 elderly patients with atrial fibrillation: Results from the All Nippon AF In the Elderly (ANAFIE) Registry. Eur. Heart J. Qual Care Clin. Outcomes. 8(2), 202\u2013213 (2022).","journal-title":"Eur. Heart J. Qual Care Clin. Outcomes."},{"key":"51776_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2020.101092","volume":"61","author":"L Bencivenga","year":"2020","unstructured":"Bencivenga, L. et al. Atrial fibrillation in the elderly: A risk factor beyond stroke. Ageing Res. Rev. 61, 101092 (2020).","journal-title":"Ageing Res. Rev."},{"issue":"11","key":"51776_CR44","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jacc.2016.06.034","volume":"68","author":"J Steffel","year":"2016","unstructured":"Steffel, J. et al. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling. J. Am. Coll. Cardiol. 68(11), 1169\u20131178 (2016).","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"51776_CR45","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12916-020-01870-w","volume":"18","author":"C Wilkinson","year":"2020","unstructured":"Wilkinson, C. et al. Clinical outcomes in patients with atrial fibrillation and frailty: Insights from the ENGAGE AF-TIMI 48 trial. BMC Med. 18(1), 401 (2020).","journal-title":"BMC Med."},{"key":"51776_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.archger.2022.104661","volume":"101","author":"M Akishita","year":"2022","unstructured":"Akishita, M. et al. Frailty and outcomes in older adults with non-valvular atrial fibrillation from the ANAFIE registry. Arch. Gerontol. Geriatr. 101, 104661 (2022).","journal-title":"Arch. Gerontol. Geriatr."},{"issue":"2","key":"51776_CR47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/2048872618758931","volume":"7","author":"D Walker","year":"2018","unstructured":"Walker, D. et al. Editor\u2019s Choice - Frailty and the management of patients with acute cardiovascular disease: A position paper from the Acute Cardiovascular Care Association. Eur. Heart J. Acute Cardiovasc. Care 7(2), 176\u2013193 (2018).","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"issue":"4","key":"51776_CR48","first-page":"1249","volume":"25","author":"I Savelieva","year":"2023","unstructured":"Savelieva, I. et al. EHRA expert consensus document on the management of arrhythmias in frailty syndrome, endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). EP Eur. 25(4), 1249\u20131276 (2023).","journal-title":"EP Eur."},{"key":"51776_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.911393","volume":"9","author":"Y Wei","year":"2022","unstructured":"Wei, Y. et al. Contemporary survival and anticoagulation of patients with atrial fibrillation: A community based cohort study in China. Front. Cardiovasc. Med. 9, 911393 (2022).","journal-title":"Front. Cardiovasc. Med."},{"issue":"3","key":"51776_CR50","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1002\/ehf2.14361","volume":"10","author":"X Peng","year":"2023","unstructured":"Peng, X. et al. Gender-specific prevalence and trend of heart failure in China from 1990 to 2019. ESC Heart Fail. 10(3), 1883\u20131895 (2023).","journal-title":"ESC Heart Fail."},{"issue":"10","key":"51776_CR51","first-page":"1577","volume":"20","author":"M Ruiz Ortiz","year":"2018","unstructured":"Ruiz Ortiz, M. et al. Inappropriate doses of direct oral anticoagulants in real-world clinical practice: Prevalence and associated factors. A subanalysis of the FANTASIIA Registry. EP Eur. 20(10), 1577\u20131583 (2018).","journal-title":"EP Eur."},{"issue":"3","key":"51776_CR52","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/HYPERTENSIONAHA.119.13138","volume":"74","author":"S Park","year":"2019","unstructured":"Park, S. et al. Edoxaban versus warfarin stratified by average blood pressure in 19 679 patients with atrial fibrillation and a history of hypertension in the ENGAGE AF-TIMI 48 trial. Hypertension. 74(3), 597\u2013605 (2019).","journal-title":"Hypertension."},{"issue":"8","key":"51776_CR53","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.29333","volume":"5","author":"GYH Lip","year":"2022","unstructured":"Lip, G. Y. H. et al. Risk levels and adverse clinical outcomes among patients with nonvalvular atrial fibrillation receiving oral anticoagulants. JAMA Netw. Open. 5(8), e2229333 (2022).","journal-title":"JAMA Netw. Open."},{"issue":"8","key":"51776_CR54","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1161\/STROKEAHA.116.013540","volume":"47","author":"NS Rost","year":"2016","unstructured":"Rost, N. S. et al. Outcomes with edoxaban versus warfarin in patients with previous cerebrovascular events: Findings from ENGAGE AF-TIMI 48 (effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction 48). Stroke. 47(8), 2075\u20132082 (2016).","journal-title":"Stroke."},{"issue":"8","key":"51776_CR55","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1161\/STROKEAHA.121.038239","volume":"53","author":"M Paciaroni","year":"2022","unstructured":"Paciaroni, M. et al. Recurrent ischemic stroke and bleeding in patients with atrial fibrillation who suffered an acute stroke while on treatment with nonvitamin K antagonist oral anticoagulants: The RENO-EXTEND study. Stroke. 53(8), 2620\u20132627 (2022).","journal-title":"Stroke."},{"issue":"5","key":"51776_CR56","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.3390\/jcm12051870","volume":"12","author":"TF Chao","year":"2023","unstructured":"Chao, T. F. et al. Prescribing patterns and outcomes of edoxaban in atrial fibrillation: One-year data from the global ETNA-AF program. J. Clin. Med. 12(5), 1870 (2023).","journal-title":"J. Clin. Med."},{"issue":"12","key":"51776_CR57","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1016\/j.hrthm.2020.07.022","volume":"17","author":"YH Chan","year":"2020","unstructured":"Chan, Y. H. et al. Off-label dosing of non\u2013vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation. Heart Rhythm. 17(12), 2102\u20132110 (2020).","journal-title":"Heart Rhythm."},{"issue":"5","key":"51776_CR58","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/ehjcvp\/pvab004","volume":"7","author":"SR Lee","year":"2021","unstructured":"Lee, S. R. et al. Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation. Eur. Heart J. Cardiovasc. Pharmacother. 7(5), 415\u2013423 (2021).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"18","key":"51776_CR59","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","volume":"383","author":"K Okumura","year":"2020","unstructured":"Okumura, K. et al. Low-dose edoxaban in very elderly patients with atrial fibrillation. N. Engl. J. Med. 383(18), 1735\u20131745 (2020).","journal-title":"N. Engl. J. Med."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51776-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51776-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51776-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T12:08:52Z","timestamp":1706875732000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-51776-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["51776"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-51776-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]},"assertion":[{"value":"18 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.-S.M. has received honoraria from BristolMyers Squibb, Pfizer, Johnson & Johnson, Boehringer-Ingelheim, Bayer and Daiichi Sankyo for giving lectures. No fees are directly received personally. J.D., Y.Y. and J.X. are employees of Daiichi Sankyo (China) Holdings Co., Ltd, Shanghai, China. M.U. and C.C. are employees of Daiichi Sankyo Inc. Basking Ridge, New Jersey, USA. All remaining authors have no disclosures.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2778"}}